The Chesapeake Bay Area Chapter of ISPE was established in 1994 to meet the needs of the growing pharmaceutical and biotech industries in the area. Today, they continue to support the local industries and provide education, training and networking events to members and non-members alike.
The Chesapeake Bay Area Chapter of ISPE was established in 1994 to meet the needs of the growing pharmaceutical and biotech industries in the area. Today, they continue to support the local industries and provide education, training and networking events to members and non-members alike.
The pharmaceutical industry stands at the cusp of a transformative era, where the integration of sustainability within the supply chain is not just a trend, but a necessity
Although parenteral products make up only 1% of global pharmaceutical prescriptions by volume, at list price they now make up nearly half of global sales value, a percentage
In 2020, CSL initiated a benchmarking activity with a small group of peer companies identified through ISPE to explore creation and maturation of asset management programs at
Join our ISPE CBA Education Committee as they host a conversation about discerning the difference between commissioning, validation, and qualification as well as computer...
This signature gathering is not just an opportunity to learn but also to connect. From emerging talents to seasoned executives in drug manufacturing, supply chain, devices and equipment and services, and global...
The 2024 ISPE Biotechnology Conference will bring together leading pharmaceutical and biopharmaceutical manufacturers, technology providers, academic scientists, and international regulators to network, share insights...
2023-2025 We are pleased to share the 2023–2025 ISPE Strategic Plan video, which reflects an ongoing commitment to our mission and vision and outlines our priorities for the next three years. Hear from ISPE International...
The explosive growth of advanced therapy medicinal products (ATMPs), particularly cellular therapeutics, has driven steady investment in facilities capable of manufacturing these therapeutics at scale . Meanwhile, the industry is collectively moving to adapt to...